SNX Rides Earnings Momentum as Analysts Lift Targets

Positioning in the lending market is about as relaxed as it gets. Short interest is only 2.2% of the free float, roughly 1.75 million shares, and borrow availability is extraordinarily loose: for every share currently borrowed, there are more than 35 available to lend. That ratio has tightened somewhat over the past two weeks, with availability falling from levels that were effectively uncapped in mid-September, but the borrow market is nowhere near stressed. Cost to borrow has drifted up to 0.51%, about 17% higher week-on-week and 50% above a month ago, still trivially cheap in absolute terms. Short interest itself edged up about 2.5% over the week after dipping on Tuesday. None of this points to meaningful short conviction; the stock simply is not a high-conviction bear target.

Options tell a slightly more nuanced story. The put/call ratio has moved to 0.49, well above its 20-day average of 0.30 and about 1.4 standard deviations higher. That is not yet an extreme reading on a 52-week basis, where the ratio has ranged from 0.15 to 0.92, but the direction is notable. Through most of August and early September the ratio sat below 0.20, consistent with a strongly call-skewed book. The shift higher in PCR over the past two weeks coincides with the stock's recovery from its post-earnings drop, suggesting some investors are buying protection into the rally rather than chasing calls outright.

The earnings history deserves attention. The September 24 print sent the stock down 8.6% on the day, and it remained 5.6% lower five days out. The prior quarter's release, in late June, generated a 3% gain on day one but a 7.7% loss over the following week. That pattern of initial reactions fading or reversing is worth bearing in mind. The next earnings event is scheduled for January 5, 2027, giving the stock 90 days to consolidate or extend the post-drop recovery.

Ownership is worth a brief note. T. Rowe Price added 2.52 million shares in the quarter to September 30, lifting its stake to 3.5% of shares outstanding and making it one of the more significant recent buyers at the institutional level. FMR (Fidelity) added nearly 800,000 shares to reach 7.9%. BlackRock added 290,000 shares and remains the largest holder at 9.2%. Brave Warrior Advisors cut its position by 1.6 million shares in the June quarter, reducing to 1.8%. No activist 13D filings are on the register. Insider activity over the past 90 days has been net negative, with the CFO, CLO, CEO and Hyve chair Dennis Polk all filing tax-withholding transactions on October 5 following what appears to be a vest event. Polk also sold 1,300 shares in mid-September under a pre-arranged 10b5-1 plan. These are routine mechanics rather than conviction signals.

The ORTEX alt data layer flags one unusual reading: retail attention, measured as the combined z-score of Wikipedia page views and ORTEX stock-page visits, ran nearly 3.3 standard deviations above the stock's own 90-day average around September 25. That spike in retail interest came immediately after the earnings release and target-upgrade wave. No alt-data dataset for SNX has been measured as a leading indicator of its reported figures, so the attention reading is colour rather than a forward signal.

With 90 days to the January print, the key question is whether Hyve's extraordinary growth pace and the Q3 guidance for 22% midpoint billings growth can offset the expected margin compression. The trajectory of borrow cost and options skew in the weeks ahead will show whether the cautious hedging tone in the options market persists or fades as the results settle in.